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A B S T R A C T   
Background: The impact of medical research is usually judged on the basis of citations in the serial literature. A 
better test of its utility is through its contribution to clinical practice guidelines (CPGs) on how to prevent, di-
agnose, and treat illness. This study aimed to compare the parameters of lung cancer research papers with those 
cited as references in lung cancer CPGs from 16 countries, and the Cochrane Collaboration. These comparisons 
were mainly based on bibliographic data compiled from the Web of Science (WoS). 
Methodology: We examined 7357 references (of which 4491 were unique) cited in a total of 77 lung cancer CPGs, 
and compared them with 73,214 lung cancer papers published in the WoS between 2004 and 2018. 
Results: References used by lung CPGs were much more clinical than the overall body of research papers on this 
cancer, and their authors predominantly came from smaller northern European countries. However, the leading 
institutions whose papers were cited the most on these CPGs were from the USA, notably the MD Anderson 
Cancer Center in Texas, the Memorial Sloan Kettering Cancer Center, New York, and the Mayo Clinic in 
Rochester, Minnesota. The types of research cited by the CPGs were primarily clinical trials, as well as three 
treatment modalities (chemotherapy, radiotherapy and surgery). Genetics, palliative care and quality of life were 
largely neglected. The median time gap between papers cited on a lung CPG and its publication was 3.5 years 
longer than for WoS citations. 
Conclusions: Analysis of the references on CPGs allows an alternative means of research evaluation, and one that 
may be more appropriate for clinical research than citations in academic journals. Own-country references show 
the direct contribution of research to a country’s health care, and other-country references show the esteem in 
which this research has been held internationally.   
1. Introduction 
1.1. The burden from the disease, and previous studies 
Globally, lung cancer is one of the leading causes of, mostly avoid-
able, mortality and morbidity. According to the World Health Organi-
zation (WHO) it accounted for 16.2 % of the world total of Disability- 
Adjusted Life Years (DALYs) attributable to cancer in 2000, and 17.1 
% in 2015 [1,2]. As the world becomes better off economically, and 
people live longer, cancer tends to increase and there is increased 
exposure to risk factors such as tobacco [3]. Lung cancer, which 
accounted for only 1.18 % of all DALYs in 2000, had increased its toll to 
1.56 % in 2015, or by 32 %. The increase was lower in Europe (+11 %), 
but much higher in Asian countries (+50 %), and in Africa (+65 %). 
However, it was actually negative (-11 %) in Canada and the USA, 
probably because of aggressive measures to prevent smoking [4,5]. 
Although there is evidence [6,7] that research plays a major role in 
the improvement of the outcomes in non-communicable diseases and 
mental disorders, it appears that lung cancer does not attract the volume 
of research that its disease burden would warrant [8]. The reasons 
behind this are multi-factorial, not least because policy-makers view 
control of tobacco as their prime objective rather than research into lung 
cancer [9,10]. There are efforts by many governments to make cigarettes 
more expensive, to make them less attractive through packaging 
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regulations, and to restrict where smoking can take place [11,12] 
although there is a considerable lack of enforcement in many countries 
[13]. An understanding of the impact of investment into lung cancer 
research is a crucial step to the redressing of the policy balance between 
the support for lung cancer research and the improvement of public 
health measures to control tobacco. 
Lung cancer research, as determined by papers in the Web of Science 
(WoS, © Clarivate Analytics), has increased quite rapidly in terms of 
output in recent years [8], but this expansion is due almost entirely to 
China, which accounted for one third of the world total lung cancer 
research outputs in 2018. Most other countries have actually reduced 
their outputs of lung cancer research, relative to research on all cancer. 
Previous studies of cancer research have all demonstrated that lung 
cancer is relatively neglected within the cancer research portfolio 
compared with its share of the burden from all cancers [8]. The shortfall 
from parity is of the order of 38 % in India [14], 50 % in China [3] and 
75 % or more in Europe [15]. In seeking to further understand and 
develop proof-of-principle of the impact of research into lung cancer and 
to provide alternate measures, we have examined the citation of 
research papers on a representative sample of lung clinical practice 
guidelines (CPGs). These are being developed and published in an 
increasing range of countries as a means to encourage evidence-based 
clinical practice. 
1.2. Methods for research evaluation 
The existing bibliometric tools for research evaluation mostly only 
take account of the impact of research on other researchers. Citations in 
the literature are the main currency employed, but there are now several 
others, collectively known as "Altmetrics", which include the numbers of 
social media interactions, reads and downloads of papers. Reads and 
downloads are also (since September 2015) counted in the WoS, both in 
the last 180 days (designated U1) and since 2013 (U2). Research eval-
uation can also be based on the ratings given by the F1000 group of 
reviewers [16] for papers in biology and in medicine. Citations among 
the reference lists of patents are another important way in which 
research can be seen to lead to innovation, especially for new pharma-
ceutical drugs. Research cited in this way tends to be very basic [17]. 
However, these ratings of "quality" give little indication of how influ-
ential papers are in terms of clinical practice – the prevention of illness, 
its diagnosis, and its treatment. 
One measure of this has recently been developed in the form of the 
clinical impact® database [18] provided by Minso Solutions AB, which 
records the details of the references on CPGs. These are developed in 
many countries, initially in Europe and North America, but now in many 
other countries such as Australia, Brazil, China, India, Japan, Saudi 
Arabia and South Africa [19]. They are intended to guide clinical 
practice, and in some countries they may dictate, for example, which 
treatments (e.g., pharmaceutical drugs) will be provided under the 
public health service because they are considered to be cost-effective 
[20–22]. An evaluation of 101 CPGs in oncology demonstrated hetero-
geneity in the underpinning evidence guiding clinical practice [23]. 
There are two features of these references that have been noted since 
the first papers that examined them as a potential means for the eval-
uation of clinical research [24,25]. One is that they are predominantly 
clinical observation (as opposed to basic research), with a concentration 
on methods of treatment (e.g., chemotherapy, radiotherapy and surgery 
for cancer) rather than genetics. The second is that they over-cite 
research from the country of the CPG. [It has been demonstrated that 
most scientific papers over-cite ones from their own country [26]]. The 
relative emphasis on clinical work, and especially on clinical trials [19], 
is not surprising as the purpose of CPGs is to inform clinical practice in 
the country or region. However it does provide an alternative view of the 
utility of such research, which may be under-valued by conventional 
measures [27]. 
1.3. What this paper does 
In this paper, we examined research papers cited in the evidence base 
of a selection of 77 CPGs from eight countries, and the Cochrane 
Collaboration library, that are covered in the clinical impact® database, 
and from seven further European countries that were processed by EP 
and GL at King’s College London as part of an investigation into Euro-
pean research on five non-communicable diseases, of which cancer was 
one [15]. The list of countries and organisations is in Table 1, with their 
International Standards Organisation (ISO2) country codes. 
The objective of the study was to seek the details of the cited papers 
in the WoS and in PubMed (the Public Library of Medicine published by 
the US National Library of Medicine) and analyse their parameters so as 
to reveal their characteristics, and how these compare with the larger set 
of lung cancer research publications in the WoS. The list of papers cited 
in CPGs contained many with multiple entries because they were cited 
on several different CPGs: it seemed to us appropriate to assign extra 
credit to these papers. 
2. Methodology 
2.1. Two sets of lung cancer research papers and means of analysis 
This study uses two sets of references to research papers. The first set 
(CPGREF) consisted of references found in the 77 CPGs published be-
tween 2003 and 2018, where the references were published between 
1955 and 2019. It was created from the lung cancer CPG references from 
two data sources: the clinical impact® database [18], and from a CPG 
reference database created at KCL [28]. The second set (WLCP) con-
sisted of the world output of lung cancer research papers retrieved via 
the WoS, and published between 2004 and 2018. 
The parameters for the analyses were :  
1 the research level of the cited references on a scale from RL = 1.0 for 
clinical observation to RL = 4.0 for basic research;  
2 the countries represented in their addresses based on fractional 
counts. For example a paper with one French and two German ad-
dresses would be categorised as FR = 0.33, DE = 0.67;  
3 the leading institutions in terms of their contributions to the CPGREF 
papers from selected countries, based on fractional counts;  
4 the domain or type of the research (e.g., chemotherapy, surgery); and  
5 the gap in years between the publication of the reference and that of 
the CPG. 
2.2. The clinical impact® and the KCL databases 
A description of the clinical impact® database and the process by 
which the references were extracted from the text of the CPGs was given 
by Eriksson et al. [19]. Details of the citing CPG included the country of 
origin, date, publisher and title. The cited references were identified by 
their PubMed identifiers (PMID. usually an 8-digit number) and/or their 
Digital Object Identifiers (DOIs). These were used to find the papers in 
Table 1 
List of countries whose Clinical Practice Guidelines in lung cancer were pro-
cessed either in the clinical impact® database (ci®) or by King’s College London 
(KCL) in order to list their references.  
Country Code Team Country Code Team 
Canada CA ci® Italy IT KCL 
Cochrane Collaboration CC ci® Netherlands NL KCL 
Croatia HR KCL Norway NO ci® 
Finland FI ci® Portugal PT KCL 
France FR KCL Spain ES KCL 
Germany DE ci® Sweden SE ci® 
Greece GR KCL United Kingdom UK ci® 
Ireland IE ci® United States US ci®  
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the WoS. Of those 5575 references, 5225 were identified in the WoS (94 
%), and their bibliographic data were downloaded and transferred to an 
Excel spreadsheet by means of a MS Excel macro written by Philip Roe of 
Evaluametrics Ltd. Details of the other papers were obtained, either 
from PubMed or from Google Scholar. The CPGs from the KCL database, 
from the seven other European countries, had a total of 1796 references 
in the WoS. The CPGREF set thus had a total of 7371 cited references, 
including many with multiple entries because they were cited on two or 
more CPGs. 
2.3. Description of analyses 
We determined the research level (RL) of the papers in the two sets 
by means of a macro that counted the papers with either a "clinical" or a 
"basic" word in their title, or both [29]. These numbers gave a value 
between 1.0 and 4.0 for both the titles of the CPGREF papers (RLp) and 
for all the papers in the journals in which they were published (RL j), and 
similarly for the comparison cohort of lung cancer research papers 
(WLCP), see below. 
We used another macro to identify papers in some 12 research do-
mains or types (e.g., surgery, radiotherapy) based on words in their ti-
tles, or sometimes, journal name strings [15]. Some papers were 
classified in more than one domain, but others could not be so classified. 
In addition, we identified papers that described clinical trials, and ones 
where the role of tobacco, or smoking, was also mentioned with title 
words. 
In order to identify the leading institutions in terms of their contri-
bution to the CPGREF set, we first counted the numbers of individual 
addresses for each paper. Because some institutions are described in 
different ways, we then sought significant words from the leading ad-
dresses. For example, one was MEM SLOAN KETTERING CANC CTR, 
NEW-YORK, NY 10021, USA, and we then used an MS Excel macro to 
count the occurrences of SLOAN KETTERING in the address field, as it 
was not always the first item in the address. We then divided these 
numbers by the number of addresses (D) to give the fractional counts of 
the Sloan Kettering Cancer Center on each paper, and then summed 
them over all the references in CPGREF. A similar procedure was used on 
the WLCP file, so that the presence of individual institutions in the two 
sets of papers could be compared. 
2.4. The comparison cohort of lung cancer research papers 
For the analysis a comparison set of papers covering the world output 
of lung cancer research papers (WLCP) was needed [8]. The file of lung 
cancer research papers was obtained from the WoS by application of a 
cancer "filter" that contained the names of 185 specialist cancer journals 
and 323 title words or phrases [30]. In addition, papers had to be either 
in a respiratory journal, such as American Journal of Respiratory and 
Critical Care Medicine or Lancet Respiratory Medicine or Lung, or contain a 
title word indicative of the respiratory system, such as Lung or Trachea. 
Papers were also taken if they were in lung cancer journals, such as 
Clinical Lung Cancer or Lung Cancer, or contained the title words Lung--
Cancer or NSCLC or SCLC. The WLCP set was analysed similarly to the 
CPGREF set for the first four of the five parameters above. The param-
eters of the two sets, CPGREF and WLCP (their countries of origin and 
distribution between research domains), were compared in the corre-
sponding years, so as to show whether there were significant differences 
between the two sets of papers. 
The last analysis, of the gap between the publishing dates of the CPG 
and of its individual references, was calculated for different CPG coun-
tries, and for different research domains of the cited papers. A com-
parison was made with the corresponding gap between lung cancer 
papers in the WoS and their individual cited references. For this purpose, 
a simplified filter was used, based on the presence of the two title words, 
cancer and lung, and a sample of 500 papers from year 2017 was taken. 
These contained a total of 19,553 references whose dates could be 
determined. 
2.5. Statistical analysis 
This was concerned with the difference between the observed 
numbers of papers, and the numbers that would have been expected 
based on an assumed distribution. We used the chi-squared value for this 
difference, based on the Poisson distribution with one degree of 
freedom, and identified values that departed from those expected with 
probability < 5 % or < 0.5 %. 
3. Results 
3.1. Numbers of papers 
There were 4491 individual papers cited on the CPGs, and the 
maximum number of CPG citations for a single paper was 23 for the 
following Canadian paper: 
Browman GP, Levine MN, Mohide EA, Hayward RSA, Pritchard KI, 
Gafni A, Laupacis A. The Practice Guidelines Development Cycle - a 
Conceptual Tool for Practice Guidelines Development and Imple-
mentation. J Clin Oncol, 13(2), 1995, 502− 512 
Most of the CPGREF papers were cited on only one guideline, but 
1286 were cited on two or more, 163 on five or more, and 27 on ten or 
more. The earliest cited paper was from 1955, and there were 12 in the 
1960s, 41 in the 1970s, and 308 in the 1980s. For almost all comparisons 
between the CPGREF and WLCP sets, the differences described below 
are statistically significant with p << 0.01 % on the Poisson distribution 
with one degree of freedom. 
3.2. Countries of the researchers 
The next analysis was of the countries of the authors of the two sets of 
papers. This has changed over time: China contributed 33 % of the WLCP 
set in 2014− 18, but only 5% in 2004− 08. A comparison has therefore 
been made for two five-year periods, 2004− 08 and 2009− 13. [There 
were too few CPG references from 2014− 18 to make an analysis useful.] 
The results are shown in Table 2. For example, in 2004− 08, the US 
contribution to the CPGREF papers was 33.7 %, and its contribution to 
Table 2 
Percentage of world lung cancer papers (WLCP) by country; percentage of ref-
erences found in CPGREF by country; and ratio between published papers and 
references in CPGREF, in two quinquennia, Q1 = 2004-08 and Q2 = 2009-13, 
fractional counts. For ISO2 country codes, see Table 1. CN = China, JP = Japan, KR 













US 30.6 24.5 33.7 31.9 1.10 1.30 
UK 3.92 3.07 7.51 8.57 1.92 2.79 
IT 5.75 4.42 5.77 5.16 1.00 1.17 
NL 2.39 2.06 5.8 4.84 2.43 2.36 
CA 2.42 2.51 5.93 4.29 2.45 1.71 
DE 4.93 3.64 5.59 4.12 1.13 1.13 
ES 2.59 2.16 1.67 3.73 0.65 1.73 
FR 4.91 3.48 3.77 3.32 0.77 0.95 
SE 0.83 0.56 1.74 1.54 2.08 2.73 
NO 0.52 0.41 1.13 0.967 2.15 2.38 
GR 1.52 1.12 1.29 0.437 0.85 0.39 
AT 0.47 0.43 0.332 0.294 0.71 0.69 
IE 0.31 0.25 0.34 0.206 1.11 0.83 
FI 0.33 0.23 0.128 0.189 0.39 0.81 
HR 0.08 0.07 0.105 0.047 1.26 0.66 
PT 0.15 0.36 0.055 0.019 0.36 0.05 
CN 4.57 16.8 1.25 5.67 0.27 0.34 
JP 15.7 12.6 8.85 7.83 0.56 0.62 
KR 3.67 5.02 1.9 3.5 0.52 0.70 
TW 2.93 3.58 0.74 0.95 0.25 0.27  
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WLCP was 30.6 %, so the ratio was 33.7/30.6 = 1.10. It was therefore 
slightly over-represented in the CPGREF compared with its contribution 
to lung cancer research in that quinquennium. Other countries, notably 
China, were under-represented. 
The presence of a country’s researchers among these CPG references 
has two separate effects. If they have contributed to the evidence base of 
CPGs from their own country, then they have been of potential benefit to 
their national health-care system. If they are cited in other countries’ 
CPGs, then they have achieved international recognition, which is an 
indicator of research quality, as these references have all been selected 
because they represented good research, and were considered important 
for clinical practice. They are normally chosen as a result of a careful 
search for good evidence, on which clinical recommendations can be 
based, whereas citations in scientific papers are given for all sorts of 
reasons. 
Accordingly, Table 3 shows the presence of individual countries’ 
researchers both on own country CPGs and on other country CPGs, in the 
two quinquennia, as ratios of their percentage presence in lung cancer 
research in each time period. There was a total of 4487 CPGREFs from 
2004− 18 for which address data were available. Of these, for example, 
the US CPGs cited 148 references, and the other 4487− 148 = 4339 
references were cited on the CPGs from other countries (and interna-
tional organisations). The US contribution to these 148 references was 
66.3 papers, or 44.8 %. This compares with the US percentage presence 
in WLCP of 15,307/67,730 = 22.6 %, so the ratio is 44.8/22.6 = 1.98, or 
2.0 to two significant figures. In the CPGs from other countries, the US 
fractional count presence was 1382 papers, or 31.8 % of 4339, so the 
ratio was 31.8/22.6 = 1.5. All the countries’ research (except for that of 
Ireland) is over-cited in their own CPGs, as would be expected.. Their 
over-citation internationally is again mostly more than unity, except for 
Finland. 
3.3. The leading research institutions in lung cancer 
The leading institutions among those contributing to the CPGREF are 
listed in Table 4 for the time period from 2004− 18. They are the Me-
morial Sloan Kettering Cancer Center in New York, the MD Anderson 
Cancer Center in Houston, Texas, and the Mayo Clinic in Rochester, 
Minnesota. The numbers are fractional counts, and are compared with 
the corresponding data for the WLCP from the same years. [For example, 
a paper with five addresses of which two were from the Memorial Sloan 
Kettering Cancer Center would count 0.4 of a paper to either total.] Both 
counts are also given as percentages of the total numbers of papers (4694 
and 73,214, respectively), and the ratio between them, showing which 
institutions’ papers are relatively the most cited in CPGs. However, there 
is a similar bias to that for countries, although most of the leading in-
stitutions are from countries that are well represented among the CPGs 
that were processed in the clinical impact® database or by KCL. There 
were five pharma companies with a strong presence among the CPG 
references, AstraZenneca plc, Eli Lilly Inc., F Hofmann La Roche s.a., 
Pfizer Inc., and Sanofi Aventis s.a. Their contributions are the sum of 
their explicit financial acknowledgements, and their presence among the 
addresses, without double counting, but with both elements being 
fractionated. 
3.4. The different types of lung cancer research 
The mean research level of the CPGREF papers was RLp = 1.23, and 
that of the journals in which they were published was RLj = 1.44, 
somewhat more basic. The corresponding values for the WLCP set were 
RLp = 2.03 and RL j= 2.06. So the CPG references were clearly much 
more clinical than those in the WLCP set, in keeping with earlier findings 
[24,25]. 
The next analysis was of the types of research, or research domains, 
in WLCP and in the CPGREF. The time period was the 15 years, 
2004− 18, and the results are in Fig. 1, and are given as percentages of 
the respective totals, 67,882 and 4694. The biggest differences are for 
clinical trials (CLIN) which are almost the largest contributor to the CPG 
references, and genetics (GENE), which are one of the least (compared 
with their contribution to lung cancer research), together with epide-
miology (EPID). The three treatment modes, drug treatment (DRUG, 
including both conventional chemotherapy and targeted therapy), 
radiotherapy (RADI, 19 %) and surgery (SURG, 17 %) all contribute 
relatively much more to the CPG references than they do to lung cancer 
research. One third of the CPGREF set report research on drug treat-
ment. Palliative care (PALL) and quality-of-life research (QUAL), which 
make tiny contributions to the WLCA papers, have a somewhat bigger, 
but still small, presence among the CPGREF papers, as does screening 
(SCRE). Few of either set make any reference to smoking or tobacco 
(TOBA) as a cause of lung cancer. 
3.5. The time gap between CPGs, and research papers, and their 
references 
The last analysis was of the gap in time between the year of CPG 
publication and those of their cited references. Overall, the mean gap 
was 9.8 years, but it varied between 15.5 years for Germany and 6.2 
years for France, see Fig. 2. This was a larger gap than the corresponding 
one for prostate cancer, 8.2 years [19]. (The standard errors of the two 
means were 0.09 and 0.07 years, so the difference was statistically 
highly significant.) It was also larger for seven of the nine countries for 
which there were CPGs. There was also a variation in the rapidity with 
which research in different domains was incorporated in the CPG evi-
dence. For surgery and epidemiology it was nearly 11 years, but for the 
relatively recently developed targeted chemotherapy it was only 4.6 
years. A comparison with the dates of the references on a sample of lung 
cancer research papers (from year 2017) showed that the median gap 
between publication of a CPG and its references is 3.5 years longer than 
Table 3 
Presence of each country with lung cancer CPGs among its own CPG references (fractional counts) (Own CU or country), and among the CPG references from other 
countries (Other CU or country), for references that have addresses, and percentages of these references (Own %, Other %), and ratios to the percentage presence of the 
country in lung cancer research (WLCP) 2004-18. For ISO2 country codes, see Table 1.  
ISO2 WLCP Own refs Own CU Own % Ratio Other refs Other CU Other % Ratio 
US 22.6 148 66.3 44.8 2.0 4339 1382 31.8 1.5 
UK 2.81 344 45.3 13.2 4.7 4143 300 7.2 2.6 
IT 4.25 116 9.6 8.3 2.0 4371 232 5.3 1.2 
NL 1.72 367 46.9 12.8 7.4 4120 185 4.5 2.6 
CA 2.20 809 54.2 6.7 3.0 3678 172 4.7 2.1 
DE 3.39 595 66.6 11.2 3.3 3892 157 4 1.2 
FR 3.32 236 15.8 6.7 2.0 4251 145 3.4 1.0 
ES 2.04 145 13 9 4.4 4342 110 2.5 1.2 
SE 0.51 629 29 4.6 9.1 3858 41.3 1.1 2.2 
NO 0.40 369 22.3 6 15 4118 29 0.7 1.8 
IE 0.23 226 0.2 0.1 0.3 4261 11.8 0.3 1.2 
FI 0.19 159 1 0.6 2.7 4328 5.5 0.1 0.7  
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for WoS lung cancer research papers and their references. 
4. Discussion 
We have sought to evaluate countries’ and research institutions’ 
contributions to lung cancer research through their influence on CPGs 
from 15 countries and the Cochrane Collaboration. This is, of course, 
only one measure of the impact of the research papers, and has several 
limitations. First, only a rather small number of research papers are cited 
at all on CPGs, whereas the majority of research papers are cited at least 
once in the serial literature. Moreover, the likelihood of being cited 
varies greatly with the research domain. Second, some of the CPG ref-
erences are not to lung cancer research papers. We found that some 78 % 
of them (that were published in the 15 years, 2004− 18) were in our 
WLCP file. This percentage varied between 91 % for drug treatments and 
only 23 % for palliative care. Some 18 % of the papers not on lung cancer 
were on some other aspects of the lung. Only 1% were concerned with 
CPG development or their use. 
As expected, important parameters for success were the conduct of 
clinical trials, research on the three main methods of treatment, and for 
the work to be patient-centred (i.e., clinical) rather than basic research. 
The countries with the relatively greatest impact were the smaller ones 
in northern Europe. Research from the countries in East Asia had 
comparatively little influence on the set of CPGs that we examined, even 
though almost all of their papers (> 99 %) in the WoS were written in 
English. This may reflect both a bias against research outputs from this 
region, but also different approaches to patient management. The 
average time gap between CPG publications and their references was 
almost ten years, two years longer than for lung cancer research papers 
in the WoS, but the difference in the median time gaps was 3.5 years. 
This means that the evidence base of some of these CPGs was not very 
recent, particularly for Germany (Fig. 2); it was better for France and 
Spain, and for Canada and the USA. It is also notable that new evidence 
for pharmaceuticals was incorporated far more rapidly than, say, for 
surgery. This again may reflect relative biases for and against these 
modalities, but also may reflect the paucity of high-quality practice 
research emanating from the surgical community. 
However, the numbers of papers from different countries are inevi-
tably biased because some countries were not represented among the 
CPG publishers; there were varying numbers of CPGs from the different 
countries (17 from Canada, six each from France and Spain, but only one 
from many countries) and varying numbers of references from the in-
dividual CPGs (one CPG from Germany had 1272 references, but two 
others had only 2 references each). At the bottom of the table are four 
East Asian countries which did not have CPGs in our collection. All four 
were under-cited in the European and North American CPGs, but Jap-
anese and South Korean lung cancer research had higher ratios of clin-
ical impact than those of China and Taiwan. 
The publications cited in CPGs are normally chosen, we assume, as a 
result of a careful search and systematic review for good evidence 
grading, on which clinical recommendations can be based, in contrast to 
citations in scientific papers which are not systematic. With traditional 
bibliometric measures appearing to under-estimate clinical research 
[27] and CPG citation analyses tending to favour clinical research as 
seen in this paper and others [19,24,25], this approach appears to be a 
valuable way to assess the impact of clinical lung cancer research, 
especially in view of the systematic process used to find and cite good 
evidence in the CPGs, and the influence of CPGs on health care practice. 
The study has some limitations, notably that the selection of CPGs 
was not systematic, nor did we ascertain whether these were "actively" 
being utilised by the various lung cancer clinical communities. Some 
countries’ lung cancer CPG collections had rather few references in total, 
usually because there was only one CPG. Not all their references were 
found in the WoS, but the shortfall (which only affected the analysis of 
addresses) was less than 5%. This is a rather new means for the evalu-
ation of clinical research, and so the methodology for its deployment has 
not yet been fully validated. 
The calculations of the leading pharmaceutical companies’ contri-
butions to the two databases, CPGREF and WLCP, are under-estimates 
because the majority of the attributions were based on explicit ac-
knowledgements, which only appeared in the WoS after 2009. Papers 
from 2009− 18 accounted for 82 % of the WLCP set from 2004− 18, but 
only 51 % of the CPGREF set. There were therefore far fewer explicit 
acknowledgements to the five pharma companies in Table 4 than would 
have occurred if the time distributions of the two sets of papers had been 
similar. 
5. Conclusions  
• The analysis of the references on lung cancer CPGs shows which 
countries’ and institutions’ research has had most influence on 
clinical practice both in their own countries and internationally 
Table 4 
The leading research institutions and companies contributing to the references 
cited on the selected lung cancer CPGs (CPGREF), fractional counts, and the 
corresponding contributions to lung cancer research (WLCP), 2004-18. The 
percentages of the totals, and the ratio between them. Company contributions 
are the sum of explicit and implicit acknowledgements, but the former are only 
available for papers from 2009-18.  





Memorial Sloan Kettering Cancer 
Center, New York, USA 
86.7 469 1.93 0.64 3.0 
Univ Texas, MD Anderson Cancer 
Center, Houston, TX 77030, USA 
80.0 977 1.78 1.33 1.3 
Mayo Clinic, Rochester, MN, USA 61.0 345 1.36 0.47 2.9 
Vrije Univ Amsterdam, Netherlands 56.5 265 1.26 0.36 3.5 
Harvard Univ, Beth Israel 
Deaconess Med Ctr, Boston, MA, 
USA 
42.1 486 0.94 0.66 1.4 
Duke Univ, Med Ctr, Durham, NC, 
USA 
39.6 257 0.88 0.35 2.5 
Massachusetts General Hospital, 
Boston, MA, USA 
39.2 292 0.87 0.40 2.2 
Washington Univ, St Louis, MO, 
USA 
36.9 235 0.82 0.32 2.6 
Univ Toronto, Toronto, Canada 32.0 236 0.71 0.32 2.2 
National Cancer Center, Tokyo, 
Japan 
31.7 386 0.71 0.53 1.3 
Princess Margaret Hosp, Toronto, 
Canada 
28.9 163 0.64 0.22 2.9 
Sungkyunkwan Univ, School of 
Medicine, Seoul, South Korea 
27.9 361 0.62 0.49 1.3 
Univ Pittsburgh, School of 
Medicine, USA 
27.6 320 0.62 0.44 1.4 
Univ Health Network, Toronto, 
Canada 
27.2 136 0.61 0.19 3.2 
Univ North Carolina, Dept Med, 
Chapel Hill, NC, USA 
26.6 174 0.59 0.24 2.5 
Seoul National Univ, College of 
Medicine, Seoul, South-Korea 
25.8 501 0.57 0.69 0.8 
Univ Hospital, Freiburg, Germany 25.5 163 0.57 0.22 2.6 
Dana Farber Cancer Institute, 
Boston, USA 
24.4 222 0.54 0.30 1.8 
Institut Gustave Roussy, Villejuif, 
France 
22.4 182 0.50 0.25 2.0 
Univ Chicago, Chicago, IL 60637, 
USA 
21.9 176 0.49 0.24 2.0 
Karolinska Institutet, Stockholm, 
Sweden 
21.3 171 0.47 0.23 2.1       
AstraZeneca plc, Macclesfield, 
England 
39.7 255 0.88 0.38 2.3 
Eli Lilly & Co, Inc., Indianapolis, 
USA 
36.2 190 0.58 0.28 2.1 
F Hofmann LaRoche s.a., Basel, 
Switzerland 
32.8 258 0.73 0.38 1.9 
Pfizer Inc., New York, NY, USA 22.8 153 0.51 0.22 2.3 
Sanofi Aventis s.a., Paris, France 21.2 71 0.47 0.11 4.5  
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• Such research is very clinical (i.e., patient-orientated), contains many 
clinical trials papers, and ones on the three main treatment methods 
(chemotherapy, radiotherapy, surgery)  
• This method of research evaluation is more appropriate for clinical 
studies and trials, which tend to receive fewer journal citations than 
basic work, and may therefore be under-appreciated based on 
traditional bibliometric indicators. 
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